Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?Andrea Botticelli, Paolo Marchetti|Journal of Translational Medicine|2018Cited by 129
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC PatientsIlaria Grazia Zizzari, Chiara Napoletano, Alessandra Di Filippo et al.|Journal of Personalized Medicine|2020Cited by 44
Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with CancerIlaria Grazia Zizzari, Chiara Napoletano, Alessandra Di Filippo et al.|Clinical Cancer Research|2022Cited by 30
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cellsAlessio Ugolini, Marianna Nuti, Ilaria Grazia Zizzari et al.|EBioMedicine|2020Cited by 17
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast CancerPier Paolo Maria Berton Giachetti, Carmen Criscitiello, Stefania Morganti et al.|JAMA Network Open|2025Cited by 11